BBOT BridgeBio Oncology Therapeutics, Inc.

CIK 0001869105 17 ready 8-Ks latest June 22, 2026, 4:05 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline Risk accumulating: repeated leadership change (5)

Ready 8-Ks 17

Latest filing June 22, 2026, 4:05 PM ET

Top materiality 0.90

Event mix m_and_a ×6 · other_material ×4 · leadership ×4

Sentiment 7 pos · 0 neg · 10 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for BBOT

Highest-materiality recent filing

BridgeBio Oncology closes SPAC merger; raises $260.9M PIPE, $381.8M total gross proceeds

August 13, 2025, 7:59 PM ET M&A materiality 0.90 positive item 1.01 item 2.01 item 3.02 item 9.01 item 4.01 item 3.03 item 5.03 item 8.01 item 5.01 item 5.02 item 5.05 item 5.06 item 7.01 ◈ Governance Changes ×4◈ M&A Transactions

Closing on Aug 11, 2025: Helix domesticated to Delaware, merged with BBOT subsidiary; new name BridgeBio Oncology Therapeutics, ticker BBOT.
PIPE of $260.9M (24.3M shares at $10.7173) plus $120.9M trust; $76.3M redeemed by 7.1M public shares.

Read filing →

June 22, 2026, 4:05 PM ET other material materiality 0.25 neutral item 5.02 item 5.07 ◈ Shareholder Votes ×2◈ executive_change

Director Michelle Doig resigns; shareholders elect two Class I directors at annual meeting

Michelle Doig resigned as Class I director upon completion of her term on June 16, 2026; resignation not due to any disagreement.
May 12, 2026, 5:07 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

BBOT Q1 net loss widens to $42.1M; cash $388.9M funds ops into 2028; pipeline shows early efficacy

Net loss $42.1M vs $22.1M YoY; R&D spend $39.8M on advancing three RAS programs.
April 29, 2026, 7:59 PM ET leadership materiality 0.40 neutral item 5.02 ◈ executive_change ×4

BridgeBio Oncology enters consulting agreement with former CEO Eli Wallace; equity vesting continues for 12 months

Dr. Wallace provides R&D advisory services for 12 months retroactive to April 21, 2026.
April 23, 2026, 7:59 PM ET leadership materiality 0.65 neutral item 5.02 item 7.01 item 9.01

BBOT appoints Pedro Beltran as CEO, Idan Elmelech as COO, and Neil Kumar as Executive Chairman

Pedro Beltran, previously CSO, succeeds Eli Wallace as President and CEO effective April 20, 2026; also named Class III director.
March 26, 2026, 7:59 PM ET leadership materiality 0.25 neutral item 5.02

BridgeBio Oncology appoints Peter Lebowitz as independent director; NCG, Compensation committees; option grant

Board size increased to nine; Lebowitz appointed as Class I director.
March 5, 2026, 6:59 PM ET earnings materiality 0.55 neutral item 2.02 item 9.01 ◈ Earnings Releases

BBOT reports Q4 net loss $38.8M; cash runway into 2028; pipeline advances

Q4 2025 net loss $38.8M (vs $19.7M in Q4 2024); full year net loss $134M (vs $74.3M).
January 7, 2026, 6:59 PM ET other material materiality 0.85 positive item 8.01 item 9.01

BBOT reports 65% ORR for BBO-8520, first panKRAS response in PDAC, no hyperglycemia with BBO-10203

BBO-8520 monotherapy: 65% ORR (11/17), 66% 6-month PFS, including one complete response; all 5 STK11/KEAP1 co-mutant patients achieved PR.
November 12, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

BBOT Q3 2025 net loss $44.8M; cash $468.3M funds operations into 2028

Net loss of $44.8M vs $17.3M in Q3 2024; R&D expenses $35.1M, G&A $14.1M.
August 13, 2025, 7:59 PM ET M&A materiality 0.90 positive item 1.01 item 2.01 item 3.02 item 9.01 item 4.01 item 3.03 item 5.03 item 8.01 item 5.01 item 5.02 item 5.05 item 5.06 item 7.01 ◈ Governance Changes ×4◈ M&A Transactions

BridgeBio Oncology closes SPAC merger; raises $260.9M PIPE, $381.8M total gross proceeds

Closing on Aug 11, 2025: Helix domesticated to Delaware, merged with BBOT subsidiary; new name BridgeBio Oncology Therapeutics, ticker BBOT.
August 6, 2025, 7:59 PM ET M&A materiality 0.75 positive item 7.01 item 9.01

Helix retains ~$120M trust (60%+) after redemptions; PIPE adds ~$261M for BBOT deal

Retained ~$120M in trust (~60%+ of original) after redemptions; 2nd lowest biotech de-SPAC redemption rate since 2022.
August 4, 2025, 7:59 PM ET M&A materiality 0.75 positive item 5.07

Helix shareholders approve all proposals for business combination with BridgeBio Oncology Therapeutics

Business Combination Proposal approved: 17.3M FOR, 2.1M AGAINST (82.55% quorum).
July 11, 2025, 7:59 PM ET M&A materiality 0.55 positive item 7.01 item 9.01

BridgeBio Oncology SPAC merger S-4 effective; shareholder vote set for Aug 4, 2025

SEC declared Registration Statement on Form S-4 effective for Helix/BBOT business combination.
March 3, 2025, 6:59 PM ET M&A materiality 0.85 neutral item 1.01 item 3.02 item 9.01

Helix Acquisition Corp. II to merge with BridgeBio Oncology Therapeutics in $461M deal

Equity value of $461M; BBOT stockholders to receive shares of PubCo common stock.
February 28, 2025, 6:59 PM ET M&A materiality 0.85 positive item 7.01 item 9.01

BBOT to merge with Helix II SPAC in $450M deal; public listing expected Q3 2025

Total proceeds ~$450M from Helix trust (~$196M) and $260M PIPE led by Cormorant, including Deerfield, Novo Holdings, Wellington.
February 10, 2025, 6:59 PM ET leadership materiality 0.35 neutral item 5.02 item 9.01

Helix Acquisition Corp. II appoints Albert A. Holman, III to its Board of Directors

Albert A. Holman, III appointed on Feb 8, 2025 as Class III independent director.
February 20, 2024, 6:59 PM ET other material materiality 0.50 neutral item 8.01 item 9.01

Helix Acquisition Corp. II completes $184M IPO and $5M private placement; trust funded

IPO of 18.4M Class A shares at $10.00 each included full exercise of 2.4M over-allotment shares.
February 14, 2024, 6:59 PM ET other material materiality 0.75 neutral item 1.01 item 3.02 item 5.02 item 5.03 item 8.01 item 9.01 ◈ executive_change ×2◈ Governance Changes◈ Material Agreements

Helix Acquisition Corp. II closes $184M IPO, including full over-allotment

Closed IPO of 18.4M Class A shares at $10.00 each; gross proceeds $184M.